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ARTICLE

New insights into the clinical and molecular spectrum of the
novel CYFIP2-related neurodevelopmental disorder and
impairment of the WRC-mediated actin dynamics
A full list of authors and affiliations appears at the end of the paper.
Purpose: A few de novo missense variants in the cytoplasmic
FMRP-interacting protein 2 (CYFIP2) gene have recently been
described as a novel cause of severe intellectual disability, seizures,
and hypotonia in 18 individuals, with p.Arg87 substitutions in the
majority.
Methods: We assembled data from 19 newly identified and all 18
previously published individuals with CYFIP2 variants. By
structural modeling and investigation of WAVE-regulatory complex (WRC)-mediated actin polymerization in six patient fibroblast
lines we assessed the impact of CYFIP2 variants on the WRC.
Results: Sixteen of 19 individuals harbor two previously described
and 11 novel (likely) disease-associated missense variants. We
report p.Asp724 as second mutational hotspot (4/19 cases).
Genotype–phenotype correlation confirms a consistently severe
phenotype in p.Arg87 patients but a more variable phenotype in p.
Asp724 and other substitutions. Three individuals with milder

INTRODUCTION
CYFIP2 encodes the cytoplasmic fragile X mental retardation
protein (FMRP) interacting protein 2. It is thought to play an
important role in neurodevelopment by linking FMRPdependent local transcription with signaling-dependent remodeling of the cytoskeleton as part of the WAVE-regulatory
complex (WRC).1 The WRC is a key regulator of actin
dynamics and consists of WASF (also known as WAVE),
CYFIP1/2, NCKAP1, ABI, and BRICK1 (or their homologs). In
the basal state the heteropentameric WRC is intrinsically
inhibited by CYFIP due to the sequestration of the activitybearing VCA domain of WASF. Binding of the small GTPase
RAC1 to CYFIP induces conformational changes of the WRC,
which release the VCA domain to trigger Arp2/3-induced actin
polymerization at distinct membrane sites.2 Accordingly, the
WRC signaling pathway plays a crucial role in important
neurodevelopmental processes such as axon guidance and
regulation of synapse morphology.1,3
Recently, de novo missense variants affecting a small number
of amino acids and one late-truncating variant in CYFIP2 have
been associated with intellectual disability (ID), seizures, and
muscular hypotonia (MIM 618008).4,5 Initially, in 2018

phenotypes carry putative loss-of-function variants, which remain
of unclear pathogenicity. Structural modeling predicted missense
variants to disturb interactions within the WRC or impair
CYFIP2 stability. Consistent with its role in WRC-mediated actin
polymerization we substantiate aberrant regulation of the actin
cytoskeleton in patient fibroblasts.
Conclusion: Our study expands the clinical and molecular
spectrum of CYFIP2-related neurodevelopmental disorder and
provides evidence for aberrant WRC-mediated actin dynamics as
contributing cellular pathomechanism.
Genetics in Medicine (2021) 23:543–554; https://doi.org/10.1038/s41436020-01011-x
Keywords: intellectual disability; epilepsy; CYFIP2; WAVEregulatory complex (WRC); WASF

Nakashima et al. described three de novo CYFIP2 variants in
four unrelated individuals with early-onset epileptic encephalopathy, all affecting the arginine at position 87, and suggested a
gain-of-function effect on the WASF signaling pathway.4
Subsequently, we reported that not only p.Arg87 variants, but
also a variety of spatially clustering de novo variants are the
cause of a new neurodevelopmental disorder characterized by
intellectual disability and seizures in 12 patients.5 We predicted
all of the detected variants to decrease the stability of the WRC,
thereby reducing the inhibitory effect of CYFIP2 on WASF
activity and eventually resulting in a gain of function of the
WASF pathway.5 With two additional reported individuals
harboring recurrent p.Arg87 variants, a total of only 18
individuals with CYFIP2 variants have been described to date.6,7
In this study, we considerably increase the number of
individuals harboring a variety of CYFIP2 variants by
reporting 19 additional cases. Genotype–phenotype correlation confirms a profound phenotype for substitutions at the
mutational hotspot p.Arg87 and demonstrates a more variable
phenotype associated with a novel recurrent variant and with
several unique missense alterations, while there is currently no
evidence that loss-of-function variants lead to a similarly
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severe phenotype. Our studies in primary fibroblast cultures
of six affected individuals demonstrate that the WRCmediated actin dynamics are disturbed by the CYFIP2
missense variants.

MATERIALS AND METHODS

1234567890():,;

Patients

The herein described cohort of 19 novel individuals (I1–I19)
was recruited through personal communication following our
initial report5 and the GeneMatcher Database8 from Germany, France, the United Kingdom, the United States,
Canada, Brazil, and New Zealand. The CYFIP2 variant was
identified by trio-exome sequencing (individuals 1, 2, 3, 4, 6,
7, 8, 9, 10, 12, 13, and 18) or single-exome sequencing with
subsequent parental testing by Sanger sequencing (individuals
5, 11, 14, 17, and 19). Individual 16 and his mother as well as
individual 15 underwent sequencing of the autism/intellectual
disability (ID) Xpanded panel from GeneDx, with subsequent
Sanger sequencing of the father of individual 15. All reported
exonic variants are described according to the CYFIP2
reference transcript NM_001291722.1 encoding for
NP_001278651.1, in line with the current HGVS nomenclature (v19.01, varnomen.hgvs.org). Intronic variants are named
based on the genomic reference sequence NC_000005.10. All
reported variants have been submitted to the Leiden Open
Variation Database (LOVD) accessible at www.LOVD.nl/
CYFIP2 (individual IDs 00301307–00301325).
Ethics statement

This study was performed as part of a research study
approved by the ethics commission of the Canton of Zurich
(ID PB_2016-02520 [SIV 11/09]). Genetic testing in collaborating centers was performed either in the setting of routine
diagnostic testing without the requirement for institutional
ethics approval or within research settings approved by the
ethical review board of the respective institutions (Ethics
Committee of the Medical Faculty of the University of Bonn,
approval numbers 131/08 and 024/12; DDD ethics approval
from NHS REC Cambridge South, approval number 10/
H0305/83; Ethics Committee of the Dijon University
Hospital, approval numbers ID RCB: 2016-A01347-44 and
CPP EST I: 2016/38). Written informed consent for genetic
testing, for publication of mutational and clinical data, and for
publication of patient photos was obtained from the
individual’s parents or legal guardian.
RNA analysis

RNA was extracted from whole blood of individual 17 and
six controls using the PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland) and transcribed reversely using SuperScript III First-Strand Synthesis System
(ThermoFisher Scientific, Waltham, MA, USA). PCR on
complementary DNA (cDNA) was performed using specific
primers located in exons 18 and 22 of CYFIP2 and the
products were analyzed by agarose gel electrophoresis.
Distinct bands were extracted using the QIAquick Gel
544
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Extraction Kit (Qiagen, Venlo, the Netherlands) and
analyzed by Sanger sequencing.
Structural variant modeling

The effect of the variants was modeled in silico on the basis of
the crystal structure of the WAVE-regulatory complex as
previously described.5 RasMol9 was used for structure analysis
and visualization. The effect of the variants on
CYFIP2 stability and binding affinity to the other WRC
proteins was assessed using BindProfX10 and FoldX.11
Fibroblast cultures

Primary fibroblast cultures were established from skin
biopsies of individual 8 (p.(Asp724Tyr)), individual 9
(p.(Asp724Gly)), and individual 11 (p.(Glu468Asp)) of the
current study as well as of P1 (p.(Arg87Cys)), P6
(p.(Ile664Met)), and P12 (p.(Tyr108His)) previously reported
by Zweier et al.,5 and of three unaffected individuals as
controls. Fibroblasts were cultured in DMEM supplemented
with 10% fetal bovine serum and 1% penicillin–streptomycin
(all Gibco, Life Technologies, Carlsbad, CA) and tested
negative for infection with Mycoplasma.
Migration assays

Wound healing assays were performed three times in
duplicates using black glass bottom 24-well plates with
culture inserts (ibidi, Gräfelfing, Germany). Ten thousand
fibroblasts were seeded in both wells of the insert in full
medium and cells were grown to a confluent monolayer for
24 hours. A consistently sized gap was created by removing
the inserts; cells were washed and incubated in medium
supplemented with 10 pg/ml of human platelet derived
growth factor BB (PDGF) (P3201, Sigma-Aldrich, St. Louis,
Missouri). Migration was assessed by multiframe live cell
imaging at 37 °C and 5% CO2 every 30 minutes for 24 hours
with a 5× objective on a Zeiss AxioObserver Z1 widefield
microscope. Images were batch processed by enhancing
contrast before using a pipeline in Ilastik12 for segmentation
into cell-free and cell-covered area, which was then quantified
using CellProfiler.13 The cell-free area was plotted in
GraphPad Prism 8.3 (GraphPad Software, La Jolla, CA) and
values in the linear phase (from 0 to 15 hours) were fitted with
a linear regression, which was used to calculate the time to
half gap and migration speed. Statistical significance of
differences in relation to three controls was calculated using
one-way analysis of variance (ANOVA) and a significance
level of p < 0.05.
Phalloidin staining

Fibroblasts were seeded on Poly-D-Lysine coated coverslips in
24-well plates and allowed to attach for about 1.5 hours before
changing to a serum-free medium for 24 hours. Cells were
stimulated with 100 ng/ml PDGF in full medium at 37 °C for
5 minutes, then were washed with warm phosphate-buffered
saline (PBS) and fixed with 3.7% methanol-free formaldehyde
for 10 minutes at room temperature. For the staining, cells
Volume 23 | Number 3 | March 2021
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were permeabilized with 0.1% Triton X-100 for 15 minutes at
room temperature, incubated with phalloidin conjugated to
Alexa Fluor 568 for 60 minutes at room temperature,
counterstained with DAPI, and mounted with ProLong Gold
Antifade Mountant (ThermoFisher Scientific). Images for
quantification of dorsal ruffles were taken on a Zeiss
AxioObserver Z1 with a 25× oil objective. Experiments
were repeated three times and at least 200 cells were counted
for each coverslip. Data were analyzed using Prism 8.3
(GraphPad Software, San Diego, CA, USA). Statistical
significance of differences in relation to three controls was
calculated using one-way ANOVA and a significance level of
p < 0.05.

RESULTS
We identified 16 individuals with likely disease-associated
missense variants in CYFIP2 and three individuals with
putative loss-of-function (LoF) variants of unknown significance (Table 1).
A novel recurrent variant and several unique missense
variants are associated with variable phenotypes

The 16 individuals with likely disease-associated missense
variants harbored 11 novel and two recurrent substitutions in
CYFIP2 (Fig. 1a). Three of these carry the previously reported
hotspot variant p.(Arg87Cys),4–6 and two harbor novel
substitutions of the arginine at this position (p.(Arg87His)
and p.(Arg87Ser)). Moreover, we establish the aspartate at
protein position p.724 as a new recurrently affected residue
mutated in four individuals (p.(Asp724His), p.(Asp724Gly),
and p.(Asp724Tyr)).
An overview of inheritance mode, conservation, computational predictions, presence in gnomAD, and available
experimental evidence is given in Table 1 for all CYFIP2
missense variants. All variants reported in the present study
are absent from gnomAD v2.1.1 and affect highly conserved
amino acids, except p.(Thr490Met) (individual 12), which was
detected once in gnomAD (minor allele frequency of
0.00003185) and affects a moderately conserved amino acid.
All variants were predicted to be deleterious by SIFT,
PolyPhen-2, and MutationTaster, apart from p.(Arg87Ser),
p.(Met311Thr), and p.(Met456Val) that show benign predictions in PolyPhen-2. De novo inheritance was confirmed for
all 12 individuals where both parental samples were available
for testing, while in four individuals only one parental sample
could be obtained. According to the guidelines of the
American College of Medical Genetics and Genomics
(ACMG), 10 variants in 13 individuals were classified as
pathogenic or likely pathogenic, while three missense variants
(p.(Met456Val) in individual 14, p.(Phe888Ser) in individual
15, and p.(His1206Tyr) in individual 16) had to be formally
classified as variants of unknown significance due to
incomplete segregation testing. Nevertheless, based on their
absence in control populations, multiple lines of computational evidence supporting deleterious effects, their location in
the tertiary structure, and the result of our mutational
GENETICS in MEDICINE | Volume 23 | Number 3 | March 2021

modeling indicating similar effects as predicted for clearly
pathogenic variants, we assume also these three missense
variants are likely causative for the phenotype. Thus we
considered all 13 missense variants to be likely diseaseassociated variants.
In all individuals of this cohort harboring missense variants
developmental delay (DD) was noted (at a median age of 6.5
months; range 6 weeks–2 years): 14/16 with global DD and 2/
16 with normal motor but delayed language development
(Table 2, Supplementary Table S1). Intellectual disability was
classified as severe or profound in 9 of 14 evaluated
individuals, as moderate in 4/14, and as mild in 1/14 cases
(according to Diagnostic and Statistical Manual of Mental
Disorders, 5th Edition [DSM V] criteria). Individuals 1 and 4
were too young for evaluation of ID with an age of 1 year 4
months or 5 months, respectively, at last investigation. About
half of the individuals in this cohort were reported to have
epilepsy (8/16, and suspected in individual 5) with onset at a
median age of 5 months (range neonatal–14 years). Generalized tonic–clonic seizures (6/8) and epileptic spasms (4/8)
were the most prevalent seizure types. Electroencephalogram
(EEG) findings were variable, with hypsarrhythmia reported
in 4/8 individuals. Two individuals were seizure-free on
antiepileptic polytherapy, while six remained refractory to
treatment. Ten of 16 individuals showed generalized or
truncal muscular hypotonia, combined with limb hypertonicity in two cases. The majority of individuals presented with a
head circumference (HC) in the lower range (11/16
individuals with HC < -1.0 SD score). Microcephaly with a
HC below 2 standard deviations was diagnosed in 5/16
individuals of the current cohort. Dysphagia was reported in
seven individuals; three of them were dependent on gastric
tube feeding. Variable visual problems were present in six
individuals, and sleep difficulties were reported in seven
individuals. Morphological features revealed a shared but not
clearly recognizable facial gestalt including high, narrow
forehead; apparent hypertelorism; depressed nasal bridge;
bulbous nasal tip; full cheeks; everted lip vermilion; and long
tapered fingers in several individuals (Fig. 1b). All individuals
are alive at their age at last evaluation (5 months to 22 years).
A collation of the clinical features from all the cases
(Supplementary Table S1) and case reports for each case
can be found in the Supplement.
No evidence that loss-of-function variants lead to a
similarly severe phenotype

Three individuals harbored heterozygous CYFIP2 variants for
which a (partial) loss of one allele product is expected (Fig. 1a
and Table 1). Individual 18 harbored the de novo variant
p.(Lys501*) while individual 19 carried the variant
p.(Ser258Glnfs*2) with unknown segregation. In individual
17 the splice variant c.2058-1G>C was detected and shown to
be absent in the mother. The variant resulted in an aberrant
in-frame transcript (lacking 58 codons) and an aberrant
out-of-frame transcript (p.(Glu686_Ser744delinsAsp) and
p.(Tyr687*), Supplementary Fig. S1). Individual 19 had mild
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Table 1 Novel, recurrent, and previously reported likely disease-associated variants in CYFIP2 and putative loss-of-function CYFIP2 variants of unclear
pathogenicity.
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ID and epilepsy while individuals 18 and 17 were both
affected by language delay, behavioral problems, and microcephaly. Of note, individuals 18 and 17 had a family history of
language delay not segregating with the variant and the
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parents of individual 19 are consanguineous. A detailed
clinical description is provided in the case reports in the
Supplement. Note that the clinical data of these individuals
are not included in Table 2.
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Fig. 1 CYFIP2 variants and morphological features of affected individuals. (a) Schematic drawing of the CYFIP2 gene in chromosomal region 5q33.3
with known and novel variants identified. (Likely) pathogenic variants are shown above and putative loss-of-function variants are depicted below the gene
scheme. Red labeling represents recurrent variants, and bold letters indicate variants detected in the present study. All variants were shown to have occurred
de novo except those marked with # (not maternal), § (not paternal), or $ (segregation unknown). Variant nomenclature and gene structure according to
NM_001291722.1 with exons numbered from 1 to 32 consecutively and NC_000005.10 for intronic sequences. Regions coding for the conserved protein
domains DUF1394 and FragX_IP are depicted in light green and light blue, respectively (according to the National Center for Biotechnology Information
[NCBI] conserved domain database). (b) Morphological features of individuals with likely disease-associated variants in CYFIP2. Note a shared but not clearly
recognizable facial gestalt including high, narrow forehead; apparent hypertelorism; depressed nasal bridge; bulbous nasal tip; full cheeks; everted lip
vermilion; and long tapered fingers in several individuals. Composite facial appearance in younger and older individuals is shown in F2GY and F2GO,
respectively (created by Face2Gene [FDNA Inc., Boston, MA, USA] with ten photos of nine individuals from this study and Zweier et al.5 each).

Table 2 Main clinical features in all CYFIP2 patients with recurrent and unique likely disease-associated variants (published
previously and in the current study).
Feature

Arg87 substitutions
n = 15a

Ile664 substitutions
n = 2a

Asp724 substitutions
n = 5a

Non-recurrent sites
n = 12a

All CYFIP2 patients
n = 34a

ID/DD
Severe/profound
Moderate
Mild
Too young to
classify
Behavioral
problems
Epilepsy
Microcephalyb
Muscle tone
anomalies
cMRI anomalies
Visual problems
Feeding difficulties

15/15
12
0
0
3

2/2
1
1
0
0

5/5
4
1
0
0

12/12
6
4
1
1

34/34 (100%)
23 (68%)
6 (17%)
1 (3%)
4 (12%)

3/8

1/2

2/5

9/12

15/27 (56%)

15/15
10/14
12/14

1/2
2/2
2/2

2/5
1/5
5/5

8/12
3/12
7/12

26/34 (76%)
16/33 (48%)
26/33 (79%)

9/14
7/9
9/11

0/1
1/2
0/2

1/5
3/5
3/5

4/12
4/12
3/12

14/32 (44%)
15/28 (54%)
15/30 (50%)

cMRI cerebral magnetic resonance imaging, DD developmental delay, ID intellectual disability.
a
Patient numbers are given only for those where the respective information was available, therefore the total count can be lower than the number of patients harboring
the respective variant.
b
Including relative microcephaly.

CYFIP2 is indicated to be intolerant to both missense (z =
6.01) and loss-of-function (probability of LoF intolerance
[pLI] = 1) variants in gnomAD. However, no such LoF
sequence variants or small structural aberrations have been
reported in patients so far. It remains unclear if the putative
LoF variants detected in our three individuals cause or
contribute to the observed phenotype.
Structural modeling of the missense variants predicts
effects on WRC or CYFIP2 stability

We mapped each of the previously and currently reported
CYFIP2 missense variants onto the available crystal structure of
human WRC and classified the predicted effects on
CYFIP2 stability and CYFIP2 affinity to its interaction partners
(Supplementary Table S2). Our estimates of changes in binding
affinity within the WRC predicted a significant reduction of the
binding affinity for 15 of 20 variants that could be modeled. As
we have reported previously, Arg87 and Asp724 are located at
the interface to WASF1 in the three-dimensional protein fold
(Fig. 2a, b)5 and form direct intermolecular interactions to α6and C-helices of WASF1. CYFIP2 variants affecting these
recurrently mutated positions disturb these interactions and
therefore favor the release of the activity-bearing VCA domain
of WASF1. Substitutions of Arg87 are additionally predicted to
cause destabilization of the CYFIP2 structure due to a loss of
intramolecular interactions. Met456 and Tyr690 are both
548

located in the interface with NCKAP1 (Fig. 2a, c). The
predominant effect of the p.(Tyr690Cys) is on the interaction
with NCKAP1, whereas p.(Met456Val) is predicted to mainly
affect the stability of CYFIP2 itself (Supplementary Table S2).
The interaction of Glu468 with BRICK1 is likely weakened by
the p.(Glu468Asp) variant (Fig. 2a, d). Met311 and Phe888 are
buried in the CYFIP2 structure (Fig. 2a, e, f). The variants
affecting these residues result in disturbed interactions in the
protein core and thus probably impact CYFIP2 stability. The
p.(His1206Tyr) exchange is not expected to significantly affect
protein stability or WRC interactions. However, His1206 is
close to the mapped RAC1 D binding site of CYFIP,14 and we
therefore speculate that this variant influences WRC activation
by affecting RAC1–CYFIP2 interaction. The effects of
p.(Thr490Met) could not be modeled due to the incomplete
structural information in the respective region of the crystal
structure.
Missense variants impair dorsal ruffle formation in patient
fibroblasts

As our structural modeling predicted the CYFIP2 variants to
affect WASF activity, we investigated the effect on actin
cytoskeleton reorganization upon growth factor stimulation
by staining filamentous actin with phalloidin in fibroblast
cultures of all six consenting affected individuals. We did not
observe apparent differences in lamellipodia formation.
Volume 23 | Number 3 | March 2021

| GENETICS in MEDICINE

ARTICLE

BEGEMANN et al

a
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Tyr108

Asp724
Gln725

Ile664
Glu665

Phe888
His1206

Met311

Thr490

Glu468
Ala455
Met456 Tyr690

b

c
Glu665
Tyr690

Ala455

Arg87

Ile664

Met456

Gln725
Asp724

d

e

Glu468

f

Met311
Phe888

Fig. 2 Structural location of CYFIP2 missense variants. (a) Structure of the WAVE-regulatory complex. The individual protein components are shown in
ribbon presentation and colored as follows: CYFIP2 (orange), NCKAP1 (cyan), WASF1 (green), BRICK1 (yellow), and ABI2 (red). Residues for which missense
variants were detected are shown in space-filled presentation and are colored according to the atom type. Black and gray labels denote residues identified in
the present and in previous studies, respectively. The same coloring scheme is also used for (b–f), which show enlargements of structurally relevant regions.
(b) Arg87, Ile664, Glu665, Asp724, and Gln725 (all colored according to their atom types) are located in the interface with WASF1 (green space-filled
presentation). (c) Ala455, Met456, and Tyr690 are all located in the interface with NCKAP1 (cyan space-filled presentation). (d) Glu468 is located in the
interface with BRICK1 (yellow space-filled presentation). (e) Met311 is buried in the CYFIP2 structure. All atoms closer than 5 Å to Met311 are shown in
orange space-filled presentation. (f) Phe888 is buried in the CYFIP2 structure (orange) close to the interaction site of NCKAP1 (cyan ribbon). All atoms closer
than 5 Å to Phe888 are shown in space-filled presentation.

However, a significantly reduced number of circular dorsal
ruffles (CDRs) was observed in all patient fibroblast lines
compared with fibroblasts of three controls (Fig. 3). CDRs are
ring-shaped, F-actin-rich structures that are transiently
GENETICS in MEDICINE | Volume 23 | Number 3 | March 2021

formed in response to growth factor stimulation.15 As CDRs
are implicated in preparation for cell movement, we further
investigated a possible effect of CYFIP2 variants on fibroblast
migration using a wound healing assay. A slower migration
549
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speed and consecutively an increased time to half gap closure
was observed only for the variant p.(Tyr108His), while there
was no difference in migration for the other patient fibroblasts
(Fig. 3).
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DISCUSSION
Our data on 16 new individuals harboring likely diseaseassociated CYFIP2 missense variants and three individuals
harboring LoF variants of unknown significance considerably
Volume 23 | Number 3 | March 2021

| GENETICS in MEDICINE

BEGEMANN et al

ARTICLE

Fig. 3 Phenotype in primary fibroblasts of affected individuals heterozygous for pathogenic CYFIP2 missense variants and unaffected
controls. (a) Representative images of PDGF-stimulated primary fibroblasts with phalloidin staining of F-actin. Fewer dorsal ruffles (indicated with white
arrows) were observed in patient cells compared with unaffected control cells. (b) Quantification of dorsal ruffle formation in patient and control fibroblasts.
The number of counted dorsal ruffles was normalized to cell number. Three independent experiments are shown, and at least 200 cells were analyzed in
each. (c) Representative images of wound healing assays with fibroblasts carrying the p.(Tyr108His) variant and a control line at time points 0 hours and 24
hours. (d,e) Wound healing assay analysis of (d) time to half gap and (e) migration speed of patient and control fibroblasts. Three independent experiments
with two technical replicates each were analyzed. Only fibroblasts harboring the p.(Tyr108His) variant showed a significant impairment of migration
compared with controls. Mean and standard deviation are displayed, and statistical significance was evaluated using one-way analysis of variance (ANOVA)
with p values indicated as follows: *p < 0.05, **p < 0.01, p**** < 0.0001.

broaden and delineate the genetic and phenotypic spectrum of
the novel CYFIP2-related neurodevelopmental disorder. The
new individuals with CYFIP2 missense variants presented with
similar features as reported previously, including ID/DD in all
cases, and seizures, muscular hypotonia, and microcephaly
frequently observed (Table 2, Supplementary Table S1).4–7 By
reporting on data of five further individuals harboring a
variant at the mutational hotspot p.Arg87, including two novel
substitutions, we confirm that p.Arg87 individuals show a
consistently very severe phenotype of developmental and
epileptic encephalopathy. In addition, we establish the
aspartate at protein position 724 as a novel recurrently
affected residue in CYFIP2 by describing four individuals
harboring three different substitutions. However, the total of
five Asp724 individuals (including patient 11 in Zweier et al.5)
present with a more variable phenotype ranging from
profound ID with intractable epilepsy to moderate ID without
epilepsy. In addition to the recurrently affected sites, we
contribute seven individuals with private variants affecting
novel positions in CYFIP2. Of note, two of these individuals
(I13 and I14 harboring variants p.(Tyr690Cys) and p.
(Met456Val), respectively) showed normal motor development milestones with a delay of language development only,
considerably widening the phenotypic spectrum of the
CYFIP2-related neurodevelopmental disorder.
It has been previously shown that CYFIP2 missense variants
spatially cluster in the tertiary structure and are predicted to
weaken the interaction with WASF1 or NCKAP1 leading to
enhanced WASF1 activation.5 We add six novel variants
located at the WASF1 or NCKAP1 interface and describe the
CYFIP2–BRICK1 interaction interface as a disease-associated
site affected by variant (p.(Glu468Asp)) (Fig. 2). Such
destabilization of the WRC due to disturbed protein–protein
interactions has already been experimentally supported by
demonstrating weaker interaction of CYFIP2 p.Arg87 variants
with the VCA of WASF1, the active domain that is usually
sequestered by CYFIP2 binding.4 In total, 15 of the 21 variants
observed so far are predicted to impair the interaction with
WRC members (Supplementary Table S2). Another effect
predicted by our structural modeling is a destabilization of the
CYFIP2 protein itself, which may result in impaired
interaction with the components of the WRC complex. A
change of CYFIP2 stability is predicted for 13 of the 21
variants reported. Interestingly, lower protein levels of the
CYFIP2 p.(Ala455Pro) and p.Arg87 variants compared with
wild type and other tested CYFIP2 mutants have already been
GENETICS in MEDICINE | Volume 23 | Number 3 | March 2021

observed in an overexpression model.16 However, in a single
LCL cell line established from a patient harboring the p.
(Arg87Leu) variant no changes in CYFIP2 levels were
detected.4 Nevertheless, changes of expression levels of CYFIP
proteins in neurons were reported to alter spine morphology
and the excitatory/inhibitory balance and neuronal excitability,17,18 which are considered to be one of the key
mechanisms underlying epilepsy and other neurodevelopmental disorders. Taken together, structural modeling
suggests that the mutated CYFIP2 proteins lead to impaired
WRC stability and hereby to increased WASF1 activity. The
only variant that is predicted to have no relevant impact on
binding affinity or CYFIP2 stability is p.(His1206Tyr).
However, this variant is located near the RAC1 D binding
site of CYFIP.14 Mutants of the D binding site have been
shown to result in a loss of RAC1 binding and impaired
morphology and function of actin-based cell protrusions.14,19
Hence, we assume that the p.(His1206Tyr) variant may affect
actin polymerization through a distinct pathomechanism.
Notably, the phenotype of the individual (I16) with moderate
ID and no seizures was not apparently different from the
other individuals.
To substantiate the effect of CYFIP2 variants on WASF1
activity in vitro we investigated actin cytoskeleton reorganization in six patient fibroblast lines, which carried variants at
the WASF1 or BRICK1 interaction interface. In all fibroblast
lines an impaired formation of CDRs was observed (Fig. 3), a
process already shown to require WASF1 activity.15 Actin
dynamics and CDRs are important for cell movement.20,21
However, we did not observe significant differences in cell
migration of patient fibroblasts in a wound healing assay, with
the exception of the cells harboring the previously reported5
variant p.(Tyr108His) (Fig. 3). This inconspicuous result for
five of six tested variants could be due to limited sensitivity in
the patient fibroblast model, which has lower CYFIP2
expression than the nervous system and still expresses a fully
functional protein from the wild-type allele. However,
fibroblasts carrying the p.(Tyr108His) variant did exhibit
slower migration. The respective individual, published as
patient 12 in Zweier et al., showed profound ID and epilepsy
and no clearly distinct features. Interestingly, Tyr108 is
annotated as a phosphorylation site with strong evidence in
PhosphoSitePlus,22 which is lost in the Tyr108His substitution. Signals from many different pathways including Rac
GTPase, phospholipids, and protein kinases converge at the
different subunits of the WRC to regulate its membrane
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localization and activation at the right time. Accordingly,
phosphorylation and dephosphorylation of CYFIP2 and the
WASF proteins have been shown to influence the release of
the VCA domain, actin polymerization, and dendritic spine
formation in neurons. Such phosphorylation sites include
Thr138 and Tyr151 of WASF1 that are located in the vicinity
of CYFIP2 Tyr108 at the WASF1 meander region.2,23–25
Hence, it can be speculated that lack of phosphorylation at the
mutated Tyr108 impairs signal integration and hereby WRCdependent cell motility, in addition to the disturbed dorsal
ruffle formation observed.
CYFIP2 and its effector WASF1 (or their orthologs) are
enriched in the brain26,27 and have been implicated in several
aspects of neuronal morphogenesis, including morphology of
synapses and neurites or axon pathfinding in a multitude of
models.1,3,23,28–32 Variants in both CYFIP2 and WASF1 lead to a
similar but unspecific neurodevelopmental phenotype with ID,
seizures, and muscular hypotonia, as well as microcephaly, visual
impairments and other features in some patients.5,33 RAC1,
ACTB, and ACTG1 variants have also been shown to result in
similar overlapping phenotypes.34–36 Although the exact pathomechanisms are yet to be elucidated, the current evidence from
fibroblast studies demonstrates an impairment of WRCdependent actin regulation, suggesting that a disturbed actin
regulation signaling cascade explains the neurological phenotype
of the patients in disorders linked with this pathway.
In addition to the reported CYFIP2 missense variants for
which we claim pathogenicity, we also identified three
putative loss-of-function variants. There is currently no clear
evidence derived from databases of copy-number or sequence
variants supporting pathogenicity or benignity of LoF variants
in CYFIP2. The three individuals reported in this study
harboring such variants also pose some challenges for
interpretation of their clinical relevance. The segregation
cannot be clarified in two cases, and in the third case a de
novo inheritance is established but other family members
were reported to have developmental difficulties indicating a
possible other, shared cause for the phenotype. Additionally,
no fibroblasts of individuals harboring LoF variants were
available for in vitro assessment. A potential compensation of
CYFIP2 loss of function by the highly homologous
CYFIP1 seems unlikely as multiple lines of evidence suggest
that they cannot compensate for each other; for example, their
expression was found to show cell-type specific differences
with Cyfip2 being mainly expressed in neurons, while Cyfip1
expression levels were higher in non-neuronal cells in the
mouse brain.27 Moreover, homozygous knockout in mice for
either gene is lethal, and Cyfip1 and Cyfip2 are expressed at
different developmental time points,29,37–39 and distinct
functions have been described in animal models.29,31,40
However, as all three individuals with putative LoF variants
have a milder phenotype than the individuals with de novo
missense CYFIP2 variants we conclude that the complete loss
of one allele product does not lead to the severe neurodevelopmental phenotype found in cases with pathogenic missense
variants.
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In conclusion, our data of 19 new individuals harboring
CYFIP2 variants considerably broadens the genetic and
phenotypic spectrum of the novel CYFIP2-related neurodevelopmental disorder typically caused by de novo missense
variants, while we propose that loss of one allele product leads
to a milder phenotype or may not be disease causing. Our
findings in patient fibroblasts indicate that pathogenic heterozygous CYFIP2 missense variants disturb the WRC and
consecutively the Arp2/3-induced actin polymerization that is
required for the concise temporal and spatial regulation of CDR
formation. In line with previous findings,4,5 we conclude that
the underlying mechanism is a disinhibition of WASF1 by
aberrant CYFIP2, resulting in dysregulation of the WAVEregulatory pathway.
Further work is needed to understand the functional
consequences of CYFIP2 variants on WASF activity and actin
dynamics, and to elucidate their effect on the FMRP
interaction and translation regulation not studied so far.
Additionally, future observations of CYFIP2 loss-of-function
variants or small deletions in humans will help to elucidate
the question of CYFIP2 haploinsufficiency.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436020-01011-x) contains supplementary material, which is available
to authorized users.

ACKNOWLEDGEMENTS
The authors are grateful to the participating individuals and their
families. We thank Isabelle Rouvet from the Center for Cell
Biotechnology of the Lyon University Hospital for fibroblast
cultures of patient 12 published in Zweier et al.5 Imaging and
migration assay analysis was performed with support of the
Center for Microscopy and Image Analysis, University of Zurich. A.
R. was supported by the Swiss National Science Foundation
(SNSF) grant 320030_179547. A.R. and H.S. were supported by
the Clinical Research Priority Program of the University of Zurich
(CRPP Praeclare). A.B. was supported by the Forschungskredit
Candoc by the University of Zurich grant FK-18–025. The DDD
Study (Cambridge South REC approval 10/H0305/83 and the
Republic of Ireland REC GEN/284/12) presents independent
research commissioned by the Health Innovation Challenge Fund
(grant number HICF-1009-003), a parallel funding partnership
between the Wellcome Trust and the Department of Health, and
the Wellcome Trust Sanger Institute (grant number WT098051).
The views expressed in this publication are those of the author(s)
and not necessarily those of the Wellcome Trust or the
Department of Health. K.Õ. and T.R. are supported by the
Estonian Research Council grant PRG471.

DISCLOSURE
K.M. and A. Begtrup are employees of GeneDx, Inc. The other
authors declare no conflicts of interest.
Volume 23 | Number 3 | March 2021

| GENETICS in MEDICINE

ARTICLE

BEGEMANN et al

Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional
affiliations.

REFERENCES
1.

2.
3.

4.
5.

6.
7.

8.

9.
10.

11.

12.
13.
14.

15.

16.
17.

18.

19.

20.
21.

22.
23.

Schenck A, Bardoni B, Langmann C, et al. CYFIP/Sra-1 controls neuronal
connectivity in Drosophila and links the Rac1 GTPase pathway to the
fragile X protein. Neuron. 2003;38:887–898.
Chen Z, Borek D, Padrick SB, et al. Structure and control of the actin
regulatory WAVE complex. Nature. 2010;468:533–538.
Schenck A, Qurashi A, Carrera P, et al. WAVE/SCAR, a multifunctional
complex coordinating different aspects of neuronal connectivity. Dev
Biol. 2004;274:260–270.
Nakashima M, Kato M, Aoto K, et al. De novo hotspot variants in CYFIP2
cause early-onset epileptic encephalopathy. Ann Neurol. 2018;83:794–806.
Zweier M, Begemann A, McWalter K, et al. Spatially clustering de novo
variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2,
cause intellectual disability and seizures. Eur J Hum Genet.
2019;27:747–759.
Peng J, Wang Y, He F, et al. Novel West syndrome candidate genes in a
Chinese cohort. CNS Neurosci Ther. 2018;24:1196–1206.
Zhong M, Liao S, Li T, et al. Early diagnosis improving the outcome of an
infant with epileptic encephalopathy with cytoplasmic FMRP interacting
protein 2 mutation: case report and literature review. Medicine
(Baltimore). 2019;98:e17749.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a
matching tool for connecting investigators with an interest in the same
gene. Hum Mutat. 2015;36:928–930.
Sayle RA, Milner-White EJ. RASMOL: biomolecular graphics for all. Trends
Biochem Sci. 1995;20:374.
Xiong P, Zhang C, Zheng W, Zhang Y. BindProfX: assessing mutationinduced binding affinity change by protein interface profiles with pseudocounts. J Mol Biol. 2017;429:426–434.
Delgado J, Radusky LG, Cianferoni D, Serrano L. FoldX 5.0: working with
RNA, small molecules and a new graphical interface. Bioinformatics.
2019;35:4168–4169.
Berg S, Kutra D, Kroeger T, et al. ilastik: interactive machine learning for
(bio)image analysis. Nat Methods. 2019;16:1226–1232.
McQuin C, Goodman A, Chernyshev V, et al. CellProfiler 3.0: nextgeneration image processing for biology. PLoS Biol. 2018;16:e2005970.
Chen B, Chou HT, Brautigam CA, et al. Rac1 GTPase activates the WAVE
regulatory complex through two distinct binding sites. eLife. 2017;6:
e29795.
Suetsugu S, Yamazaki D, Kurisu S, Takenawa T. Differential roles of
WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for
fibroblast cell migration. Dev Cell. 2003;5:595–609.
Lee Y, Zhang Y, Ryu JR, et al. Reduced CYFIP2 stability by Arg87 variants
Causing Human Neurological Disorders. Ann Neurol. 2019;86:803–805.
Pathania M, Davenport EC, Muir J, et al. The autism and schizophrenia
associated gene CYFIP1 is critical for the maintenance of dendritic
complexity and the stabilization of mature spines. Transl Psychiatry.
2014;4:e374.
Davenport EC, Szulc BR, Drew J, et al. Autism and schizophreniaassociated CYFIP1 regulates the balance of synaptic excitation and
inhibition. Cell Rep. 2019;26:2037–2051.
Schaks M, Singh SP, Kage F, et al. Distinct interaction sites of Rac GTPase
with WAVE regulatory complex have non-redundant functions in vivo.
Curr Biol. 2018;28:3674–3684.
Hoon JL, Wong WK, Koh CG. Functions and regulation of circular dorsal
ruffles. Mol Cell Biol. 2012;32:4246–4257.
Innocenti M. New insights into the formation and the function of
lamellipodia and ruffles in mesenchymal cell migration. Cell Adh Migr.
2018;12:401–416.
Hornbeck PV, Zhang B, Murray B, et al. PhosphoSitePlus, 2014: mutations,
PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512–D520.
Kim Y, Sung JY, Ceglia I, et al. Phosphorylation of WAVE1 regulates actin
polymerization and dendritic spine morphology. Nature. 2006;442:
814–817.

GENETICS in MEDICINE | Volume 23 | Number 3 | March 2021

24. Mendoza MC. Phosphoregulation of the WAVE regulatory complex and
signal integration. Semin Cell Dev Biol. 2013;24:272–279.
25. Lee Y, Kim D, Ryu JR, et al. Phosphorylation of CYFIP2, a component of
the WAVE-regulatory complex, regulates dendritic spine density and
neurite outgrowth in cultured hippocampal neurons potentially by
affecting the complex assembly. Neuroreport. 2017;28:749–754.
26. Sossey-Alaoui K, Head K, Nowak N, Cowell JK. Genomic organization
and expression profile of the human and mouse WAVE gene family.
Mamm Genome. 2003;14:314–322.
27. Zhang Y, Kang HR, Han K. Differential cell-type-expression of CYFIP1 and
CYFIP2 in the adult mouse hippocampus. Anim Cells Syst (Seoul).
2019;23:380–383.
28. Zallen JA, Cohen Y, Hudson AM, et al. SCAR is a primary regulator of
Arp2/3-dependent morphological events in Drosophila. J Cell Biol.
2002;156:689–701.
29. Han K, Chen H, Gennarino VA, et al. Fragile X-like behaviors and
abnormal cortical dendritic spines in cytoplasmic FMR1-interacting
protein 2-mutant mice. Hum Mol Genet. 2015;24:1813–1823.
30. Pittman AJ, Gaynes JA, Chien CB. nev (cyfip2) is required for retinal
lamination and axon guidance in the zebrafish retinotectal system. Dev
Biol. 2010;344:784–794.
31. Cioni JM, Wong HH, Bressan D, et al. Axon-axon interactions regulate
topographic optic tract sorting via CYFIP2-dependent WAVE complex
function. Neuron. 2018;97:1078–1093.
32. Shakir MA, Jiang K, Struckhoff EC, et al. The Arp2/3 activators WAVE and
WASP have distinct genetic interactions with Rac GTPases in
Caenorhabditis elegans axon guidance. Genetics. 2008;179:1957–1971.
33. Ito Y, Carss KJ, Duarte ST, et al. De novo truncating mutations in WASF1
cause intellectual disability with seizures. Am J Hum Genet.
2018;103:144–153.
34. Reijnders MRF, Ansor NM, Kousi M, et al. RAC1 missense mutations in
developmental disorders with diverse phenotypes. Am J Hum Genet.
2017;101:466–477.
35. Cuvertino S, Stuart HM, Chandler KE, et al. ACTB loss-of-function
mutations result in a pleiotropic developmental disorder. Am J Hum
Genet. 2017;101:1021–1033.
36. Riviere JB, van Bon BW, Hoischen A, et al. De novo mutations in the actin
genes ACTB and ACTG1 cause Baraitser-Winter syndrome. Nat Genet.
2012;44:440–444.
37. Zhang Y, Kang H, Lee Y, et al. Smaller body size, early postnatal lethality,
and cortical extracellular matrix-related gene expression changes of
Cyfip2-null embryonic mice. Front Mol Neurosci. 2018;11:482.
38. Kumar V, Kim K, Joseph C, et al. C57BL/6N mutation in cytoplasmic
FMRP interacting protein 2 regulates cocaine response. Science.
2013;342:1508–1512.
39. Chung L, Wang X, Zhu L, et al. Parental origin impairment of synaptic
functions and behaviors in cytoplasmic FMRP interacting protein 1
(Cyfip1) deficient mice. Brain Res. 2015;1629:340–350.
40. Bozdagi O, Sakurai T, Dorr N, et al. Haploinsufficiency of Cyfip1 produces
fragile X-like phenotypes in mice. PLoS One. 2012;7:e42422.

Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike
4.0
International
License, which permits any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. If you remix,
transform, or build upon this article or a part thereof, you must distribute your
contributions under the same license as the original. The images or other third
party material in this article are included in the article’s Creative Commons
license, unless indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/.
© The Author(s) 2020

553

ARTICLE

BEGEMANN et al

Anaïs Begemann, MD1, Heinrich Sticht, PhD2, Amber Begtrup, PhD, FACMG3,
Antonio Vitobello, PhD4,5, Laurence Faivre, MD, PhD4,6, Siddharth Banka, MD, PhD7,8,
Bader Alhaddad, MD9, Reza Asadollahi, MD, PhD1, Jessica Becker, PhD10, Tatjana Bierhals, MD11,
Kathleen E. Brown, MS, CGC12, Ange-Line Bruel, PhD4,5, Theresa Brunet, MD9,
Maryline Carneiro, MD13, Kirsten Cremer, MD10, Robert Day, PhD14,
Anne-Sophie Denommé-Pichon, MD4,5, Dave A. Dyment, MD15,16, Hartmut Engels, PhD10,
Rachel Fisher, MS, CGC17, Elaine S. Goh, MD18, M. J. Hajianpour, MD, PhD19,
Lucia Ribeiro Machado Haertel, MD20, Nadine Hauer, MSc21, Maja Hempel, MD11,
Theresia Herget, MD11, Jessika Johannsen, MD22, Cornelia Kraus, PhD21,
Gwenaël Le Guyader, MD, PhD23, Gaetan Lesca, MD24,25, Frédéric Tran Mau-Them, MD, PhD4,5,
John Henry McDermott, MD7,8, Kirsty McWalter, MS, CGC3, Pierre Meyer, MD26,
Katrin Õunap, MD, PhD27,28, Bernt Popp, MD21,29, Tiia Reimand, MD, PhD27,28,30,
Korbinian M. Riedhammer, MD9,31, Martina Russo, MSc1, Lynette G. Sadleir, MD32,
Margarita Saenz, MD12, Manuel Schiff, MD33,34, Elisabeth Schuler, MD35, Steffen Syrbe, MD35,
Amelie Theresa Van der Ven, MD11, Alain Verloes, MD, PhD36,37, Marjolaine Willems, MD38,
Christiane Zweier, MD, PhD21, Katharina Steindl, MD1, Markus Zweier, PhD1 and
Anita Rauch, MD 1,39,40
1

Institute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland; 2Institute of Biochemistry, Emil-Fischer Center,
Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; 3GeneDx, Gaithersburg, MD, USA; 4INSERM UMR 1231
Equipe GAD, Université de Bourgogne, Dijon, France; 5Unité Fonctionnelle Innovation en Diagnostic génomique des maladies
rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France; 6Centre de Référence Maladies Rares «Anomalies du développement
et syndromes malformatifs», centre de génétique, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France; 7Manchester Centre for
Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester,
UK; 8Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of
Manchester, Manchester, UK; 9Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of
Munich, Munich, Germany; 10Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn,
Bonn, Germany; 11Institute of Human Genetics, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 12University of
Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Aurora, CO, USA; 13Department of Neuropediatrics, Lyon
University Hospital, Lyon, France; 14Cancer Research Laboratory, Department of Biochemistry, University of Otago, Dunedin, New
Zealand; 15Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada; 16Children’s Hospital of Eastern Ontario Research
Institute, University of Ottawa, Ottawa, ON, Canada; 17Division of Pediatric Genetics, Metabolism, and Genomic Medicine,
Department of Pediatrics, University of Michigan, Arbor, MI, USA; 18Laboratory Medicine and Genetics and Institute for Better
Health, Trillium Health Partners, Mississauga, ON, Canada; 19Department of Pediatrics, Medical Genetics, Quillen College of
Medicine, East Tennessee State University, Johnson City, TN, USA; 20Hospital Santa Catarina de Blumenau, Blumenau, Brazil;
21
Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; 22Department of
Pediatrics, University medical center Hamburg-Eppendorf, Hamburg, Germany; 23CHU de Poitiers, Poitiers, France; 24Department of
Medical Genetics, Lyon University Hospital, Lyon, France; 25CNRS UMR 5292, INSERM U1028, Claude Bernard Lyon 1 University,
Lyon, France; 26Department of Pediatric Neurology, CHU Montpellier, PhyMedExp, University of Montpellier, INSERM, CNRS,
Montpellier, France; 27Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia;
28
Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia; 29Institute of Human Genetics,
University of Leipzig Hospitals and Clinics, Leipzig, Germany; 30Department of Biomedicine, Institute of Biomedicine and
Translational Medicine, University of Tartu, Tartu, Estonia; 31Department of Nephrology, Klinikum rechts der Isar, School of
Medicine, Technical University of Munich, Munich, Germany; 32Department of Paediatrics and Child Health, University of Otago,
Wellington, New Zealand; 33Reference center for Inborn Errors of Metabolism, Necker University Hospital, APHP, Université de
Paris, Faculté de médecine Paris-Descartes, Paris, France; 34Institut Imagine, Inserm UMRS_1163, Paris, France; 35Department of
Pediatrics, University Hospital Heidelberg, Heidelberg, Germany; 36UMR1141 INSERM, Université Paris Diderot, Sorbonne Paris Cité,
Paris, France; 37Genetics Department, AP-HP, Robert-Debré University Hospital, Paris, France; 38Département Génétique Médicale,
CHRU de Montpellier, Montpellier, France; 39Zurich Center for Integrative Human Physiology, University of Zurich, Zurich,
Switzerland; 40Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.

554

Volume 23 | Number 3 | March 2021

| GENETICS in MEDICINE

